Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains

Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon

(2020) Sönke Andres et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: A Multi-Laboratory, Multi-Country Study

(2020) Koné Kaniga et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering

(2020) Brendon M. Lee et al.   PLoS Pathogens

Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran

(2020) Jalil Kardan-Yamchi et al.   Journal of Clinical Medicine

Homoplastic single nucleotide polymorphisms contributed to phenotypic diversity in Mycobacterium tuberculosis

(2020) Pornpen Tantivitayakul et al.   Scientific Reports

‘Those who cannot remember the past are condemned to repeat it’: Drug-susceptibility testing for bedaquiline and delamanid

(2019) Claudio U. Köser et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Emergence of low level delamanid and bedaquiline resistance during extremely drug resistant tuberculosis treatment

(2019) S Polsfuss et al.   CLINICAL INFECTIOUS DISEASES

Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

(2019) Shu’an Wen et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Acquisition of cross-resistance to Bedaquiline and Clofazimine following treatment for Tuberculosis in Pakistan

(2019) Arash Ghodousi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues

(2019) Conor J. Meehan et al.   NATURE REVIEWS MICROBIOLOGY

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis

(2019) Olatunde Olayanju et al.   EUROPEAN RESPIRATORY JOURNAL

Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis

(2018) Paola M. V. Rancoita et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

(2018) Gabriella Ferlazzo et al.   LANCET INFECTIOUS DISEASES

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

(2018) Matteo Zignol et al.   LANCET INFECTIOUS DISEASES

Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis

(2018) Mamoru Fujiwara et al.   TUBERCULOSIS

Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia

(2018) Elena Martinez et al.   TUBERCULOSIS

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

(2018) Jeong Seong Yang et al.   Annals of Laboratory Medicine

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study

(2018) Nazir A. Ismail et al.   EBioMedicine

Whole Genome Sequencing of Mycobacterium tuberculosis

(2018) Andrea M. Cabibbe et al.   EUROPEAN RESPIRATORY JOURNAL

Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis

(2018) Stephanie Portelli et al.   Scientific Reports

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging

(2018) Yang Li et al.   DRUG DEVELOPMENT RESEARCH

Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region

(2018) Beatriz Lopez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates

(2018) Thomas Andreas Kohl et al.   PeerJ

The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology

(2018) Conor J. Meehan et al.   EBioMedicine

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

(2017) Giovanni Migliori et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee

(2016) Harald Hoffmann et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mutations inpepQConfer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

(2016) Deepak Almeida et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid emergence ofMycobacterium tuberculosisbedaquiline resistance: lessons to avoid repeating past errors

(2016) Nicolas Veziris et al.   EUROPEAN RESPIRATORY JOURNAL

Unexpected high prevalence of resistance-associatedRv0678variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline

(2016) Cristina Villellas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Delamanid susceptibility testing ofMycobacterium tuberculosisusing the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system

(2016) Elisa Schena et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mutations in Genes for the F420Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in SpontaneousIn Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis

(2015) Hana L. Haver et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MAESTRO - multi agent stability prediction upon point mutations

(2015) Josef Laimer et al.   BMC BIOINFORMATICS

Bedaquiline susceptibility testing ofMycobacterium tuberculosisin an automated liquid culture system

(2015) Gabriela Torrea et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Identification of novel mutations associated with clofazimine resistance inMycobacterium tuberculosis: Table 1.

(2015) Shuo Zhang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

(2015) Guido V. Bloemberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crystal Structure of the Transcriptional Regulator Rv0678 ofMycobacterium tuberculosis

(2014) Abhijith Radhakrishnan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

(2014) Koen Andries et al.   PLoS One

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study

(2014) P. Miotto et al.   mBio

MMPBSA.py: An Efficient Program for End-State Free Energy Calculations

(2012) Bill R. Miller et al.   Journal of Chemical Theory and Computation

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824

(2012) Susan E. Cellitti et al.   STRUCTURE

Impact offgd1andddnDiversity in Mycobacterium tuberculosis Complex onIn VitroSusceptibility to PA-824

(2011) Silke Feuerriegel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DSX: A Knowledge-Based Scoring Function for the Assessment of Protein–Ligand Complexes

(2011) Gerd Neudert et al.   Journal of Chemical Information and Modeling

TubercuList – 10 years after

(2010) Jocelyne M. Lew et al.   TUBERCULOSIS

Crystal Structures of F420-dependent Glucose-6-phosphate Dehydrogenase FGD1 Involved in the Activation of the Anti-tuberculosis Drug Candidate PA-824 Reveal the Basis of Coenzyme and Substrate Binding

(2008) Ghader Bashiri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY